Safety and Efficacy of Baloxavir Marboxil in Influenza-infected Children 5-11 Years of Age: A Post Hoc Analysis of a Phase 3 Study.

"This post hoc analysis was funded by F. Hoffmann LaRoche Ltd and Genentech, Inc., and this funding contributed to the trial design, data interpretation and writing of this report. The authors thank Denise Kenski, PhD, of Health Interactions, Inc, for providing editorial assistance, which was funded by F. Hoffmann LaRoche Ltd and Genentech, Inc., in accordance with Good Publication Practice (GPP2022) guidelines (https://www.ismpp.org/gpp-2022). S.E.C., C.C., M.S., S.S. and S.W. are the employees of Genentech, Inc, and hold shares of Roche. L.B.M. is the employee of Roche Products Ltd and holds shares of Roche. The other authors have no conflicts of interest to disclose."

"This post hoc analysis was funded by F. Hoffmann LaRoche Ltd and Genentech, Inc., and this funding contributed to the trial design, data interpretation and writing of this report. The authors thank Denise Kenski, PhD, of Health Interactions, Inc, for providing editorial assistance, which was funded by F. Hoffmann LaRoche Ltd and Genentech, Inc., in accordance with Good Publication Practice (GPP2022) guidelines (https://www.ismpp.org/gpp-2022). S.E.C., C.C., M.S., S.S. and S.W. are the employees of Genentech, Inc, and hold shares of Roche. L.B.M. is the employee of Roche Products Ltd and holds shares of Roche. The other authors have no conflicts of interest to disclose."